Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
69452-0350-11 69452-0350 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 28, 2022 In Use
69452-0350-92 69452-0350 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 28, 2022 In Use
70121-1569-07 70121-1569 Filgrastim RELEUKO 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1571-07 70121-1571 Filgrastim RELEUKO 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
49884-0867-01 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0867-02 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 30, 2008 Jan. 31, 2020 In Use
49884-0867-05 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0867-15 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-01 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-02 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 30, 2008 Feb. 29, 2020 In Use
49884-0868-05 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-15 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-01 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-02 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 30, 2008 Feb. 29, 2020 In Use
49884-0869-05 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-15 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
45865-0598-10 45865-0598 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 3, 2015 In Use
45865-0598-30 45865-0598 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 3, 2015 In Use
00078-0675-15 00078-0675 ondansetron hydrochloride ZOFRAN 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 7, 2018 May 31, 2022 No Longer Used
00078-0676-15 00078-0676 ondansetron hydrochloride ZOFRAN 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 12, 2017 May 31, 2022 No Longer Used
17478-0547-01 17478-0547 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 In Use
51991-0065-97 51991-0065 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous May 1, 2020 May 2, 2020 No Longer Used
51991-0065-98 51991-0065 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Sept. 15, 2017 May 31, 2022 No Longer Used
68001-0366-25 68001-0366 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Oct. 5, 2018 May 31, 2022 No Longer Used
68001-0366-87 68001-0366 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Feb. 10, 2020 Aug. 24, 2021 No Longer Used
53097-0571-60 53097-0571 Dronabinol MARINOL 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 In Use
67457-0440-00 67457-0440 Ondansetron Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 10, 2017 In Use
67457-0440-22 67457-0440 Ondansetron Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 29, 2014 In Use
67877-0753-60 67877-0753 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 In Use
67877-0754-60 67877-0754 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 In Use
67877-0755-60 67877-0755 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 In Use
00006-0461-01 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-02 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-06 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 April 30, 2020 In Use
00006-0461-12 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-30 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 July 14, 2010 In Use
00006-3884-01 00006-3884 Fosaprepitant Dimeglumine Emend Ancillary Therapy Antiemetic Substance P/Neurokinin 1 July 8, 2010 July 31, 2012 No Longer Used
00006-3884-32 00006-3884 Fosaprepitant Dimeglumine Emend Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Jan. 25, 2008 July 31, 2012 No Longer Used
55513-0126-01 55513-0126 Epoetin alfa Epogen 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 30, 1989 In Use
55513-0126-10 55513-0126 Epoetin alfa Epogen 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 30, 1989 In Use
55513-0144-01 55513-0144 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0144-10 55513-0144 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0148-01 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0148-10 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0267-01 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0267-10 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0283-01 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0283-10 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0478-01 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
55513-0478-10 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
51655-0813-54 51655-0813 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 10, 2021 In Use
60760-0636-10 60760-0636 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
60760-0636-20 60760-0636 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 26, 2018 In Use
60760-0636-30 60760-0636 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 15, 2019 In Use
60760-0636-16 60760-0636 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 3, 2023 In Use
61919-0565-10 61919-0565 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 12, 2018 In Use
61919-0565-12 61919-0565 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 6, 2019 In Use
61919-0565-20 61919-0565 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 23, 2016 In Use
61919-0565-30 61919-0565 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 22, 2019 In Use
61919-0565-90 61919-0565 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 22, 2019 In Use
61919-0565-60 61919-0565 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 6, 2019 In Use
63187-0379-03 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 1, 2017 In Use
63187-0379-05 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 2, 2017 In Use
63187-0379-10 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 1, 2016 In Use
63187-0379-12 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 4, 2018 In Use
63187-0379-15 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 1, 2016 In Use
63187-0379-20 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 1, 2016 In Use
63187-0379-30 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 1, 2016 In Use
63187-0379-06 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 30, 2023 In Use
63187-0379-07 63187-0379 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 30, 2023 In Use
68071-2909-01 68071-2909 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 6, 2023 In Use
68071-2969-03 68071-2969 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 6, 2023 In Use
68788-8365-05 68788-8365 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 1, 2023 In Use
68788-8377-01 68788-8377 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 28, 2023 In Use
68788-8377-03 68788-8377 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 28, 2023 In Use
68788-8377-06 68788-8377 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 28, 2023 In Use
68788-8377-09 68788-8377 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 28, 2023 In Use
68788-8418-01 68788-8418 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 11, 2023 In Use
68788-8418-02 68788-8418 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 11, 2023 In Use
68788-8418-03 68788-8418 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 11, 2023 In Use
68788-8418-05 68788-8418 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 11, 2023 In Use
68788-8418-06 68788-8418 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 11, 2023 In Use
69367-0190-50 69367-0190 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Feb. 2, 2023 In Use
70114-0120-01 70114-0120 Pegfilgrastim-cbqv UDENYCA 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous March 6, 2023 In Use
70121-1568-07 70121-1568 Filgrastim RELEUKO 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1568-01 70121-1568 Filgrastim RELEUKO 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70518-3182-00 70518-3182 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Aug. 5, 2021 In Use
70518-3182-02 70518-3182 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 2, 2023 In Use
70518-3600-01 70518-3600 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 28, 2022 In Use
70518-3600-02 70518-3600 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 28, 2023 In Use
70518-3600-03 70518-3600 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 1, 2023 In Use
70518-3716-00 70518-3716 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 16, 2023 In Use
70934-0634-82 70934-0634 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 18, 2020 Aug. 31, 2023 In Use
70934-0634-84 70934-0634 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 13, 2021 Jan. 31, 2025 In Use
70934-0634-95 70934-0634 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 31, 2020 May 31, 2025 In Use
70934-0634-89 70934-0634 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 7, 2022 Nov. 30, 2024 In Use
70934-0809-83 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 22, 2021 Feb. 28, 2025 In Use
70934-0809-87 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 22, 2021 Feb. 28, 2025 In Use
70934-0809-88 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 16, 2021 Nov. 30, 2024 In Use
70934-0809-95 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 8, 2020 Feb. 28, 2025 In Use

Found 10,000 results in 6 milliseconds — Export these results